Based on its solid technology platforms, the company has laid out a 10-year development strategy plan: leading by new drug development which is supported by clinical and preventive medicine industries, developing in size and strength, and become one of world-renowned brands in the biomedical and pharmaceutical industry.

New Drug Development:

——Inhibitor of Bone Marrow Suppression:Because chemotherapeutic drugs have been widely used in most cancer treatments, about 30-40% of cancer patients have bone marrow suppression and impaired immune system. A substantial amount of clinical data conducted in the Commonwealth of Independent States (CIS) countries have shown that the HomeMexI injection can significantly inhibit bone marrow suppression caused by chemotherapy, and the integrative treatment is better than that of current frontline inhibitors such as G-CSF (human granulocyte colony-stimulating factor). Currently similar inhibitors generate total sales of 5 billion U.S. dollars in the present global market, and over 10 billion U.S. dollars for those used in combination with the chemotherapy regimen to protect the bone marrow. The company has identified the bone marrow suppression recovery after chemotherapy in cancer patients " as the indication for its first new drug candidate to be submitted to the U.S. FDA and the EMEA of European Union, and start the application process. It is expected to enter Phase II clinical trials in 2012, and to be approved for marketing in 2016.

——Multi-drug Resistance Reversal Agent:Multi-drug resistance is a bottleneck of today's cancer treatment. Toxicity problems cannot be solved in all countries' research and little progress is achieved. As of today, none of the multi-drug resistance reversal agents has yet been approved by U.S. FDA. A large amount of clinical data from trials conducted in the Commonwealth of Independent States (CIS) countries has shown that the company's natural botanical small molecule-compound drugs not only can reverse multi-drug resistance but also are non-toxic and safe to use. The company has confirmed this multi-drug resistance reversal agent as the second new drug candidate to be submitted to the U.S. FDA and EMEA of European Union. It is expected that it will enter Phase II clinical trials in 2013 and be approved for sale in 2017. This multi-drug resistance reversal drug not only can work synergistically with almost every type of chemotherapeutic drugs, but also can reduce the toxicity as well as enhance their efficacy. Based upon the estimated 10 million new cancer patients worldwide each year, there will be a huge market for this product.

——Diabetes:the company's new drug has different features from the existing ones such as hypoglycemic agents, and insulin etc., which can only control the disease but not reverse it. Our product may stimulate a patient's body so as to produce insulin, to gradually reverse the disease and turn the insulin and blood sugar measures back to normal level, and eventually recover. Our diabetes drug candidate is expected to enter Phase II clinical trials in 2014, and to be approved for sale in 2018.

——Hypertension:the current hypertension drugs, like those for diabetes, can only control the disease but not reverse it, while the company's new drug can stimulate stem cell growth mechanism, gradually reverse the patient's condition, turn all indications back to the normal standard, and recover. Our new drug candidate is expected to enter phase II clinical trials in 2014 and to be approved for marketing in 2018.

Because the number of diabetes and hypertensive patients is so large, the company's two unique new drugs will be able to generate huge market value.

——Peptide drugs:Although the global development of peptide drugs is still in the stage of basic research, it is evolving rapidly and on the eve of break-out. Those who have solid basic research in this field will be able to seize the opportunities. With its unique high-throughput peptide array technology platform, the company has become a world leader in developing peptide drugs after many years of research efforts and is expected to see fruitful results in the near future.